DC-MED Sp. z o.o. s.k.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis3 trials
• Crohn's disease2 trials
• Obesity2 trials
• Psoriatic arthritis2 trials
• Chronic kidney disease1 trial
• Osteoarthritis1 trial
• Psoriasis1 trial

Phase

• Phase 35 trials
• Phase 23 trials
• Phase 2/31 trial

Status

• Completed6 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Abivax S.A.2 trials
• MoonLake Immunotherapeutics AG2 trials
• Alvotech Swiss AG1 trial
• Arena Pharmaceuticals Inc.1 trial
• Boehringer Ingelheim1 trial
• and 2 more

Running trials

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in participants aged 18 years and over with active psoriatic arthritis and antiTNFα inadequate response.

  2024-516219-25-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Recruiting

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· Phase 2· Abivax S.A.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease1 recruiting

Closed trials

• Completed

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source

• Recruiting

  Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

  NCT06833749· Phase 2· KeyBioscience AG· Source

• Completed

  Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solution administered by enema to patients with mild to moderate left-sided ulcerative colitis

  2023-506917-23-00· Phase 2· Cosmo Technologies Limited· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

  2024-513569-38-00· Phase 2/3· Arena Pharmaceuticals Inc.· Source